The Journal of family practice
-
YES. Infants respond to behavioral interventions, although objective data are limited. Behavioral interventions include establishing regular daytime and sleep routines for the infant, reducing environmental noises or distractions, and allowing for self-soothing at bedtime (strength of recommendation: B, based on multiple randomized and nonrandomized studies).
-
Asthma remains a substantial health burden, despite continued treatment advances. Patients with mild or moderate asthma, even those with intermittent symptoms, are at risk for severe or fatal exacerbations. Use of short-acting beta2-agonist (SABA)-only rescue therapy is associated with an increased risk of exacerbations, beginning at about the second fill annually. ⋯ There is a window of opportunity just prior to an asthma exacerbation during which use of fast-acting bronchodilator + ICS may play a significant role in mitigating the risk of exacerbation. Patients may respond better to a combination inhaler of a fast-acting bronchodilator and an ICS as needed for rescue therapy or as part of a maintenance and rescue therapy paradigm, rather than attempting to use separate inhalers. However, there is currently no fixed-dose, fast-acting bronchodilator + ICS approved in the United States for as-needed use.
-
This UK study revealed the benefits of introducing gluten at age 4 months.
-
Chronic kidney disease (CKD) remains underrecognized by patients and clinicians in the primary care setting, largely due to its asymptomatic presentation in early stages. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have demonstrated kidney-protective effects in clinical trials-including in patients with and without type 2 diabetes (T2D)-and there are several proposed mechanisms for these benefits. Dapagliflozin and canagliflozin are SGLT2 inhibitors with indications for CKD, and only dapagliflozin is indicated for CKD in patients without T2D. Clinically relevant adverse events associated with SGLT-2 inhibitors include volume depletion, diabetic ketoacidosis, and genital mycotic infections.
-
Identify patients who are good candidates for a continuous glucose monitor (CGM) vs fingerstick self-monitoring of blood glucose (SMBG) Discuss the information provided by CGM systems Generate and interpret patient CGM data using the ambulatory glucose profile (AGP) to assess time targets established by the International Consensus on Time in Range Modify the treatment plan based on CGM data to improve patient outcomes.